Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+

Bibliographic Details
Main Authors:	Talbot, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Morgensztern, D, Ong, TJ
Format:	Conference item
Language:	English
Published:	Elsevier 2018

Similar Items